Abstract It has been shown that benidipine, a long-lasting calcium (Ca) channel blocker, may exert its protective effect against vascular disorders by increasing nitric oxide (NO) production. The purpose of the present study was to investigate whether orally administered benidipine might infl uence the membrane function in patients with essential hypertension. We measured the membrane fl uidity of erythrocytes by using an electron paramagnetic resonance (EPR) and spin-labeling method. In the preliminary study using erythrocytes obtained from healthy volunteers, benidipine decreased the order parameter (S) for 5-nitroxide stearate (5-NS) and the peak height ratio (ho/h-1) for 16-NS in the EPR spectra in vitro. The fi nding indicated that benidipine increased the membrane fl uidity and improved the microviscosity of erythrocytes. In addition, it was demonstrated that the effect of benidipine on membrane fl uidity of erythrocytes was signifi cantly potentiated by the NO-substrate, L-arginine. In the separate series of the study, we observed that orally administered benidipine for 4 weeks signifi cantly increased the membrane fl uidity of erythrocytes with a concomitant increase in plasma NO metabolite levels in hypertensive subjects. The results of the present study demonstrated that benidipine might increase the membrane fl uidity and improve the microviscosity of erythrocytes both in vitro and in vivo, to some extent, by the NO-dependent mechanism. Furthermore, it is strongly suggested that orally administered benidipine might have a benefi cial effect on the rheologic behavior of erythrocytes and the improvement of the microcirculation in hypertensive subjects.
Introduction
Abnormalities in physicochemical properties of the cell membranes may underlie the defects that are strongly linked to hypertension, stroke, and other cardiovascular diseases. [1] [2] [3] [4] [5] [6] An electron paramagnetic resonance (EPR) and spin-labeling method has been developed to elucidate the membrane fl uidity (a reciprocal value of membrane microviscosity) and perturbations of the membrane function by external agents. [4] [5] [6] We have shown previously that the membrane fl uidity of erythrocytes was signifi cantly lower in both spontaneously hypertensive rats (SHR) and patients with essential hypertension than in the normotensive controls, [7] [8] [9] and we proposed that abnormal microviscosity of the cell membranes might contribute to the pathogenesis of hypertension. With regard to the modulatory factors of membrane fl uidity, we have demonstrated that nitric oxide (NO) donor improved membrane fl uidity of erythrocytes in patients with essential hypertension, which indicated that NO could have a benefi cial effect on the rheologic behavior of erythrocytes and the microcirculation. 10 Benidipine is a novel 1,4-dihydropyridine-type of Ca channel blocker, and is characterized by a strong and longlasting antihypertensive effect. 11, 12 It has been shown that benidipine may improve the endothelial dysfunction in hypertensive rats. 13 In addition, it has been demonstrated that benidipine have a vasodilatory action in rat renal arteries and an inhibitory effect on vascular intimal thickening in mouse carotid arteries by increasing the NO production. 14, 15 In an in vitro study presented recently, we have demonstrated that benidipine signifi cantly increased membrane fl uidity of erythrocytes in normotensive volunteers. 16 However, it is still unclear whether benidipine administration might infl uence membrane function in hypertensive subjects in vivo. In the present study, in order to assess the modulatory action of the Ca channel blocker on membrane function in hypertension, we examined whether orally administered benidipine might modulate the membrane fl uidity of erythrocytes in hypertensive subjects by mean of the EPR method.
Materials and methods

Study I
Subjects
In the preliminary study, we examined the effects of benidipine on the membrane fl uidity of erythrocytes in vitro. The erythrocytes were obtained from normotensive volunteers (n = 8, male 6, female 2, age 61 ± 5 years old, mean ± SEM, blood pressure 133.7 ± 4.8/77.5 ± 3.4 mmHg, heart rate 73.5 ± 1.0 beats/min). The study was approved by a review committee, and informed consent was obtained from all subjects.
Effects of benidipine alone and in combination with Larginine on membrane fl uidity of erythrocytes in vitro Blood samples were obtained by venipuncture after a minimum of 30 min bed rest while fasting. We used heparin as the anti-coagulant (10 U of heparin/10 ml of blood). The procedure of erythrocyte preparation was shown previously. [7] [8] [9] [10] The washed erythrocytes were resuspended in the isotonic buffer (140 mmol/l NaCl, 20 mmol/l Tris-HCl, pH 7.4) at a hematocrit of 50%. The erythrocyte suspension (erythrocytes 100 µl and Tris-HCl buffer 100 µl:200 µl total) was incubated for 2 h at 37°C in the NaCl-Tris buffer (100 µL) containing benidipine (1 × 10 −7 to 1 × 10 −5 mol/l) alone, because the previous study showed that the maximal effects of benidipine and other vasoactive substances were obtained after a 2-h incubation at 37°C. 7-10 After incubation with benidipine, 100 µl of the solution containing fatty acid spin label agents (5-nitroxide stearate; 5-NS and 16-nitroxide stearate; 16-NS, 5 × 10 −5 mol/l) was added to the erythrocyte suspension. The spin-label agents were dissolved and kept at a stock solution of 0.01 mol/l in ethanol as previously described. 7 The agents were diluted in the NaCl-Tris buffer before the experiment (5 × 10 −5 mol/l). 7 The mixed solution was then incubated for 2 h at 37°C with gentle shaking, and the EPR measurements were performed.
To examine the effects of benidipine in combination with the NO-substrate, the erythrocytes (100 µl) were pretreated with the same volume of Tris-HCl solution containing Larginine (1 × 10 −3 mol/l) before the application of benidipine (1 × 10 −7 to 1 × 10 −5 mol/l). The remainder of the experiment was performed as mentioned above.
Electron paramagnetic resonance (EPR) measurements of erythrocytes
The EPR measurements were performed using an EPR spectrometer (Model Jeol JES-FE2XG, Nihon Denshi, Tokyo, Japan) with a microwave unit (Model Jeol ES-SCXA, Nihon Denshi). [7] [8] [9] [10] The procedures of the EPR measurements were described previously. [7] [8] [9] [10] For indices of membrane fl uidity, we have evaluated the values of outer and inner hyperfi ne splitting (2T′|| and 2T′⊥ in G, respectively) in the EPR spectra for 5-NS and calculated the order parameter (S) from 2T′|| and 2T′⊥. [7] [8] [9] [10] 17, 18 In the EPR spectra for 16-NS, we used the peak height ratio (ho/h-1) value for an index of the membrane fl uidity. [7] [8] [9] [10] 17, 18 The lower the values of the order parameter (S) and the peak height ratio (ho/h-1), the greater the membrane fl uidity of erythrocytes, indicating the improvement of membrane fl uidity.
Study II
In a separate series of the study, we examined the effects of orally administered benidipine on membrane fl uidity of erythrocytes and plasma NO metabolite (nitrite and nitrate) levels in hypertensive subjects in vivo. Thirteen hypertensive subjects were enrolled in the study. The study was approved by a review committee, and informed consent was obtained from all subjects. All subjects in this study were nonsmokers and had similar lifestyles and dietary habits. They were instructed to avoid any changes in dietary habits during the investigation. The subjects were divided into the benidipine-group (age 57 ± 4 years old, mean ± SEM, n = 6) receiving 4 mg/day of benidipine hydrochloride for 4 weeks and the untreated control-group (age 61 ± 3 years old, mean ± SEM, n = 7). The basal characteristics of the subjects are given in Table 1 . No subjects had not have received or were taking any other drugs such as antihypertensive agents before and during the investigation. Blood pressure monitoring and blood sampling were done before and at the end of the 4-week follow-up period. Blood sampling was performed early in the morning after subjects had fasted overnight (more than 18 h), and the EPR measurement of erythrocytes and the plasma NO metabolite analysis were performed.
NO metabolites (nitrite and nitrate) analysis
The plasma levels of the NO metabolites (nitrite and nitrate) were measured with an automated NO detector/highperformance liquid chromatography system (ENO 10, Eicom, Tokyo, Japan), as previously described. 19 
Drugs
Benidipine hydrochloride was obtained from Kyowa Hakko (Tokyo, Japan). The spin label agents, 5-NS and 16-NS, were purchased from Aldrich (Milwaukee, WI, USA). All other drugs were standard laboratory reagents of analytical grade.
Statistics
Values are expressed as mean ± SEM. In Study I, the differences between the means of the drug treatment and their corresponding controls were tested with a one-way of analysis of variance (ANOVA). The means of the different groups were analyzed by Wilcoxon's signed rank sum test.
To compare the means of the different study groups in Study II, Wilcoxon's signed rank sum test or Mann-Whitney U-test were used. A P value of less than 0.05 was accepted as the level of signifi cance.
Results
Effects of benidipine alone and in combination with Larginine on membrane fl uidity of erythrocytes in vitro
−5 mol/l) decreased the order parameter (S) for 5-NS and the peak height ratio (ho/h-1) for 16-NS obtained from erythrocyte membranes in healthy volunteers in a dose-related fashion (Fig. 1) . This fi nding showed that benidipine signifi cantly increased the membrane fl uidity and improved the membrane microviscosity of erythrocytes. In addition, it was clearly demonstrated that the effect of benidipine on the membrane fl uidity of erythrocytes was signifi cantly potentiated by the NOsubstrate, L-arginine (1 × 10 −3 mol/l), which showed no effects of its own (Fig. 1) .
Effects of orally administered benidipine on membrane fl uidity of erythrocytes and plasma NO metabolite levels in hypertensive subjects
In the next series of the study, we examined the effects of orally administered benidipine on membrane fl uidity of erythrocytes in hypertensive subjects in vivo. Orally administered benidipine for 4 weeks signifi cantly reduced the blood pressure in hypertensive subjects (Table 2 ). Further- Values are means ± SEM more, it was shown that benidipine signifi cantly decreased the order parameter (S) and the peak height ratio (ho/h-1) of the EPR spectra, and increased the membrane fl uidity of erythrocytes with a concomitant increase in plasma NO metabolite levels in hypertensive subjects (Table 2) . No other parameters such as erythrocyte count or hemoglobin level were changed after the benidipine treatment ( Table  2 ). There was no direct correlation between the blood pressure reduction and the changes in membrane fl uidity of erythrocytes or plasma NO metabolite levels (data not shown).
Discussion
Benidipine is a novel 1,4-dihydropyridine-type of Ca channel blocker, and is characterized by a strong and longacting antihypertensive effect both in vivo and in vitro. 11, 12 In the present study, we investigated the effects of orally administered benidipine on membrane fl uidity of erythrocytes in hypertensive subjects by means of the EPR and spin-labeling method. In an in vitro preliminary study, we showed that benidipine signifi cantly decreased the order parameter (S) for 5-NS and the peak height ratio (ho/h-1) for 16-NS obtained from EPR spectra of erythrocyte membranes. The fi ndings indicated that benidipine signifi cantly increased the membrane fl uidity of erythrocytes. The lack of an energy source for a long-term incubation in such an in vitro system would deplete adenosine triphosphate (ATP) and infl uence the membrane function. However, it was shown that glucose alone might affect the intracellular Ca-kinetics, 20 and we used the isotonic NaClTris buffer without glucose in this study.
Recently, it has been shown that the NO-donor might have a benefi cial effect on hemodynamics. 21 Kobayashi et al. 13 demonstrated that in an in vivo administration of benidipine increased NO synthase (NOS) activity and endothelial-type of NOS (eNOS) mRNA in the left ventricle of hypertensive rats. Yamashita et al. 15 showed that benidipine treatment enhanced eNOS expression in mouse aortas with a concomitant increase in plasma NO metabolites. Matsubara et al. 22 provided direct evidence that benidipine significantly augmented eNOS expression and total eNOS activities in human umbilical vein endothelial cells in vitro. It was also reported that benidipine increased coronary blood fl ow and improved myocardial ischemia in dogs through the NO-and cGMP-dependent mechanism in vivo. 23 These observations might propose the idea that the effect of benidipine could partially be mediated by the NO production.
In the present study, it was shown that the effect of benidipine was signifi cantly potentiated by the NO-substrate, Larginine, in vitro. The synergistic effect suggests that the action of benidipine might be, at least in part, mediated by the NO-related pathway, and confi rms our previous fi nding showing that the benidipine effect on erythrocyte membrane fl uidity was potentiated by the NO-donor, S-nitroso-N-acetylpenicillamine (SNAP), and in contrast, counteracted by the NOS inhibitors, such as N G -nitro-argininemethylester and asymmetric dimethylarginine. 16 Jubelin and Gierman 24 demonstrated that erythrocytes of rats and humans are positive for NOS, which indicated that erythrocytes possess all the cellular machinery to synthesize their own NO. Kleinbongard et al. 25 provided direct evidence that erythrocytes from humans expressed an active and functional eNOS, which was localized in the plasma membranes and the cytoplasm of erythrocytes. The authors also demonstrated that the NOS might be regulated by its substrate, Larginine. The fi ndings might propose the hypothesis that erythrocytes would synthesize and use NO to modulate their own physiology. In the previous studies, it was demonstrated that the NO donors signifi cantly improved membrane fl uidity and deformability of erythrocytes in humans. 10, 26 These previous fi ndings coupled with our present results suggest that NO might play a crucial role in the benidipine-induced alterations in membrane properties.
In the present study, we demonstrated that orally administered benidipine signifi cantly increased the membrane fl uidity of erythrocytes with a concomitant increase in plasma NO metabolite levels in hypertensive subjects. The result might be consistent with the idea that benidipine increased the membrane fl uidity of erythrocytes, at least in part, via the NO-dependent mechanism. Because mem- Table 2 . Effects of orally administered benidipine (4 mg/day) on blood pressure, membrane fl uidity (order parameter: S and peak height ratio: ho/h-l), and plasma NO metabolite levels in hypertensive subjects Values are means ± SEM # P < 0.05 between before and after the benidipine-treatment; & P < 0.05 between the benidipine group and the control group brane fl uidity is inversely correlated with membrane microviscosity, 6, 27 it would be possible that the membrane action of benidipine could be one of the mechanisms responsible for its benefi cial effects in improving the rheologic behavior of erythrocyte membranes in hypertensive subjects. We have already shown that there was no direct correlation between the blood pressure reduction and the changes in the membrane fl uidity of erythrocytes. 4 McLaren et al. 2 also reported that membrane fl uidity did not correlate with blood pressure in SHR. It seems likely that the changes in the membrane fl uidity of erythrocytes might not be a consequence of the blood pressure reduction.
Takase et al. 28 also showed that the antihypertensive therapy with benidipine signifi cantly increased the plasma NO metabolite levels in patients with essential hypertension. Recently, the measurement of NO metabolites in the erythrocytes has been performed by several investigators. [29] [30] [31] Ishibashi et al. 30 demonstrated that there was a close relationship between plasma NO and erythrocyte NO metabolite levels in humans. One hypothesis is that an increase in both plasma and erythrocyte NO might synergistically improve membrane fl uidity of erythrocytes in essential hypertension after benidipine-treatment.
In the previous study, we demonstrated that the effect of benidipine on erythrocyte membrane fl uidity might be independent of extracellular Ca. 16 On the other hand, Yang et al. 32 showed that cGMP-related endothelial relaxation was directly affected by magnesium (Mg) metabolism. It cannot be fully excluded that the effect of benidipine may merely be a consequence of the alteration of the ionic fl uxes and intracellular Ca and Mg. Further studies are necessary to assess more precisely the relationships between the benidipine treatment and NO production, and their contribution to the amelioration in membrane functions in hypertensive subjects.
In summary, the results of the present study showed that benidipine administration signifi cantly increased membrane fl uidity of erythrocytes in hypertensive subjects both in vitro and in vivo. The effects were partially mediated by the NOdependent pathway. Furthermore, it is strongly suggested that benidipine administration could have a benefi cial effect on the rheologic behavior of erythrocytes and the improvement of microcirculation in hypertensive subjects.
